Envista (NYSE:NVST) Now Covered by Analysts at Mizuho

Mizuho assumed coverage on shares of Envista (NYSE:NVST) in a research report sent to investors on Wednesday morning, Marketbeat reports. The brokerage issued an underperform rating and a $20.00 target price on the stock.

Several other brokerages have also weighed in on NVST. Robert W. Baird lifted their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Bank of America cut their target price on Envista from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Piper Sandler raised their target price on Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Wells Fargo & Company initiated coverage on Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price target for the company. Finally, Evercore ISI raised their price objective on Envista from $18.00 to $23.00 and gave the company an “outperform” rating in a report on Monday, September 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.65.

Envista Trading Down 6.5 %

Shares of Envista stock opened at $20.57 on Wednesday. Envista has a 1 year low of $15.15 and a 1 year high of $25.64. The firm has a market cap of $3.54 billion, a PE ratio of -2.65, a P/E/G ratio of 3.10 and a beta of 1.31. The stock has a fifty day moving average price of $19.96 and a 200-day moving average price of $18.34. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The firm had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. During the same period last year, the firm posted $0.43 EPS. The business’s revenue was down 4.8% compared to the same quarter last year. Equities research analysts anticipate that Envista will post 0.72 EPS for the current year.

Hedge Funds Weigh In On Envista

Several hedge funds have recently made changes to their positions in NVST. Price T Rowe Associates Inc. MD increased its stake in shares of Envista by 6.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 133,887 shares of the company’s stock valued at $2,863,000 after buying an additional 8,380 shares during the period. Tidal Investments LLC boosted its position in shares of Envista by 105.1% during the first quarter. Tidal Investments LLC now owns 20,331 shares of the company’s stock valued at $435,000 after purchasing an additional 10,420 shares in the last quarter. CWM LLC boosted its position in shares of Envista by 203.3% during the second quarter. CWM LLC now owns 14,899 shares of the company’s stock valued at $248,000 after purchasing an additional 9,986 shares in the last quarter. Profit Investment Management LLC boosted its position in shares of Envista by 44.5% during the second quarter. Profit Investment Management LLC now owns 193,429 shares of the company’s stock valued at $3,217,000 after purchasing an additional 59,608 shares in the last quarter. Finally, M&G Plc boosted its position in shares of Envista by 12.5% during the second quarter. M&G Plc now owns 306,253 shares of the company’s stock valued at $5,206,000 after purchasing an additional 33,923 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.